Expression of CD44 splicing isoforms in lung cancers: dominant expression of CD44v8-10 in non-small cell lung carcinomas

Int J Oncol. 1998 Mar;12(3):525-33. doi: 10.3892/ijo.12.3.525.

Abstract

We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Alternative Splicing*
  • Antigens, CD / analysis
  • Antigens, CD / biosynthesis*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Carcinoma, Small Cell / immunology
  • Carcinoma, Small Cell / pathology
  • Female
  • Humans
  • Hyaluronan Receptors / analysis
  • Hyaluronan Receptors / biosynthesis*
  • Immunohistochemistry
  • Lung Diseases / immunology
  • Lung Diseases / pathology
  • Lung Neoplasms / immunology
  • Lung Neoplasms / pathology*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Polymerase Chain Reaction
  • Smoking
  • Tumor Cells, Cultured

Substances

  • Antigens, CD
  • Hyaluronan Receptors